Ingen internetforbindelse — viser den gemte version af siden.

Organon & Co

USUSD
← Til Screeneren

Organon & Co (LSE:0A9W) — Biotechnology: Pharmaceutical Preparations. Antal børser, hvor selskabets aktier handles: 2. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.

Om Virksomheden

Websted
organon.com
Investorrelationer
organon.com/investor-relations/
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Hovedkontor
Oss, United States
Administrerende Direktør
Joseph T. Morrissey
Ansatte
10 000
Grundlagt
1923
Udestående Aktier
262.61 mio. pr. 2026-07-24
Et År: +1.0% · 3 år: +2.8% · 5 år: +3.6% (uden aktiesplit)
DatoAktierÆndring
24.07.2026262.61 mio.—ingen væsentlige ændringer
27.04.2026262.6 mio.+0.9%udstedelse (udvanding)
17.02.2026260.32 mio.+0.1%udstedelse (udvanding)
03.11.2025259.98 mio.—ingen væsentlige ændringer
30.07.2025259.97 mio.—ingen væsentlige ændringer
25.04.2025259.96 mio.+0.8%udstedelse (udvanding)
25.02.2025257.95 mio.+0.2%udstedelse (udvanding)
25.10.2024257.54 mio.+0.03%ingen væsentlige ændringer
30.07.2024257.47 mio.+0.1%udstedelse (udvanding)
26.04.2024257.17 mio.+0.6%udstedelse (udvanding)
20.02.2024255.64 mio.+0.01%ingen væsentlige ændringer
27.10.2023255.61 mio.+0.01%ingen væsentlige ændringer
04.08.2023255.57 mio.+0.2%udstedelse (udvanding)
28.04.2023255.06 mio.+0.3%udstedelse (udvanding)
22.02.2023254.38 mio.—ingen væsentlige ændringer
Antal aktier ifølge virksomhedens rapporter. Et aktiesplit registreres ved et spring i antallet med et helt multiplum.
Free Float
242.99 mio.
Markedsværdi
3.6 mia. USD
Insidere
0.46%
Institutionelle Investorer
84.8%
Branche (SIC)
Pharmaceutical Preparations
ISIN
US68622V1061
LEI
549300AMCKY57OK2CO56
Udbetalingsgrad
8.6%
FCF
567 mio. USD
Udbetaling / FCF
3%
Gæld
8.55 mia. USD
13 år FCF
Udbyttestreak
5 år
Indtjening, FCF og udbetalt udbytte — for de 12 måneder frem til 30.06.2026 (selskabets seneste rapport).
NAV
3.83 USD · P/NAV 3.58
Balance sheet date30.06.2026
Assets13.2 mia. USD
− Liabilities12.2 mia. USD
= NAV (aktiekapital i selskabets aktionærer)1.01 mia. USD
− Goodwill4.15 mia. USD
− Intangible assets1.11 mia. USD
= Tangible NAV−4.26 mia. USD
Aktier262 609 000
NAV per share3.83 USD
Håndgribelig NAV pr. Aktie−16.22 USD
Share price (0A9W)13.7300 USD
P/NAV3.58
NAV history
Balance sheet dateNAVNAV per share
30.06.20261.01 mia. USD3.83 USD
31.03.2026903 mio. USD3.44 USD
31.12.2025752 mio. USD2.89 USD
30.09.2025906 mio. USD3.48 USD
30.06.2025733 mio. USD2.82 USD
31.03.2025542 mio. USD2.10 USD
31.12.2024472 mio. USD1.83 USD
30.09.2024493 mio. USD1.91 USD
Beskrivelse

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

annonce

Børser og Tickere

BørsTickerValutaPrisType
US USA StocksOGN primærUSD13.74 -0.22%almindelige aktier
LSE London Stock Exchange0A9W IOBUSD13.73 +0.07%almindelige aktier

Kurs over 3 Måneder

stigningsdag faldsdag udbyttets ex-dato udbetalingsdatoHold musen over / tryk på en dag — åbnings-, luknings-, højeste og laveste kurs

Udbytte

Pr. År, LSE:0A9W: 0.08 USD (4 udb.)

Organon & Co (0A9W) udbetaler udbytte kvartalsvis. Pr. År (12 måneder op til og med den senest annoncerede betaling): 0.08 USD pr. Aktie (betalinger: 4). Det svarer til cirka 0.58% af den nuværende aktiekurs. Baseret på betalingshistorikken forventes næste ex-udbyttedato omkring 17.11.2026. Uafbrudt udbyttehistorik: 5 år.

Ex-DatoUdbetalingBeløb%TypeTicker
2026-08-142026-09-100.0200 USD0.1/0.6 %kvartalsvisLSE:0A9W
2026-05-112026-06-110.0200 USD0.2/0.6 %kvartalsvisLSE:0A9W
2026-02-232026-03-120.0200 USD0.3/1.0 %kvartalsvisLSE:0A9W
2025-11-202025-12-110.0200 USD0.3/4.6 %kvartalsvisLSE:0A9W
2025-08-152025-09-110.0200 USD0.2/6.5 %kvartalsvisLSE:0A9W
2025-05-122025-06-120.0200 USD0.2/9.7 %kvartalsvisLSE:0A9W
2025-02-212025-03-130.2800 USD1.8/7.2 %kvartalsvisLSE:0A9W
2024-11-122024-12-120.2800 USD1.5/6.0 %kvartalsvisLSE:0A9W
2024-08-162024-09-120.2800 USD1.5/6.0 %kvartalsvisLSE:0A9W
2024-05-102024-06-130.2800 USD1.5/6.0 %kvartalsvisLSE:0A9W
2024-02-232024-03-140.2800 USD1.5/6.0 %kvartalsvisLSE:0A9W
2023-11-102023-12-140.2800 USD2.4/9.8 %kvartalsvisLSE:0A9W
2023-08-17—0.2800 USD1.2/4.9 %kvartalsvisLSE:0A9W
2023-05-12—0.2800 USD1.3/5.3 %kvartalsvisLSE:0A9W
2023-02-24—0.2800 USD1.1/4.2 %kvartalsvisLSE:0A9W
2022-11-10—0.2800 USD1.2/4.7 %kvartalsvisLSE:0A9W
2022-08-12—0.2800 USD0.9/3.5 %kvartalsvisLSE:0A9W
2022-05-13—0.2800 USD0.8/2.4 %kvartalsvisLSE:0A9W
2022-02-25—0.2800 USD0.8/1.6 %kvartalsvisLSE:0A9W
2021-11-19—0.2800 USD0.9/0.9 %kvartalsvisLSE:0A9W

Største Ejere

EjerAndelAktierRapportdato
Blackrock Inc.12.21%32.06 mio.2026-06-30
Pentwater Capital Manage…6.89%18.1 mio.2026-06-30
iShares Trust-iShares Co…6.09%16 mio.2026-08-31
Vanguard Portfolio Manag…5.76%15.13 mio.2026-06-30
Vanguard Capital Managem…4.54%11.91 mio.2026-06-30
State Street Corporation3.68%9.66 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…3.17%8.33 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…2.29%6.02 mio.2026-06-30
Goldman Sachs Group Inc1.98%5.2 mio.2026-06-30
UBS Group AG1.85%4.86 mio.2026-06-30
Geode Capital Management…1.83%4.82 mio.2026-06-30
Alliancebernstein L.P.1.81%4.75 mio.2026-06-30
Man Group PLC1.59%4.18 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…1.45%3.82 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…1.15%3.01 mio.2026-06-30
NexPoint Funds I-NexPoin…1.03%2.71 mio.2026-06-30
SPDR SERIES TRUST-State…0.94%2.47 mio.2026-08-31
iShares Trust-iShares S&…0.89%2.35 mio.2026-08-31
SPDR SERIES TRUST-State…0.54%1.41 mio.2026-08-31
Fidelity Concord Street…0.49%1.3 mio.2026-07-31
ALI KEVIN (Chief Executi…≈0.11%282 7312025-05-05
WALSH MATTHEW M (Chief F…≈0.08%212 7462026-03-31
MORRISSEY JOSEPH T JR (C…≈0.05%123 1232026-03-31
STAHLER RACHEL A (Chief…≈0.04%116 1052026-03-31
FALCIONE AARON (Officer)≈0.04%101 4312026-03-31
WEAVER KIRKE (General Co…≈0.04%92 6392026-03-31
NISITA VITTORIO (Officer…≈0.03%70 6192026-03-31
KARP DANIEL (Officer)≈0.03%69 5472026-03-31
HOLZBAUR LYNETTE (Office…≈0.02%52 8502026-05-06
COX CARRIE SMITH (Office…——2025-11-12